BRPI0607323A2 - composições e uso de polipeptìdeos e kits para a detecção de anticorpo que se liga especificamente a um polipeptìdeo - Google Patents

composições e uso de polipeptìdeos e kits para a detecção de anticorpo que se liga especificamente a um polipeptìdeo

Info

Publication number
BRPI0607323A2
BRPI0607323A2 BRPI0607323-9A BRPI0607323A BRPI0607323A2 BR PI0607323 A2 BRPI0607323 A2 BR PI0607323A2 BR PI0607323 A BRPI0607323 A BR PI0607323A BR PI0607323 A2 BRPI0607323 A2 BR PI0607323A2
Authority
BR
Brazil
Prior art keywords
polypeptides
compositions
polypeptide
specifically binds
kits
Prior art date
Application number
BRPI0607323-9A
Other languages
English (en)
Inventor
Daryll A Emery
Darren E Straub
Laura Wonderling
Lisa L Herron Olson
Original Assignee
Epitopix Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epitopix Llc filed Critical Epitopix Llc
Publication of BRPI0607323A2 publication Critical patent/BRPI0607323A2/pt
Publication of BRPI0607323B1 publication Critical patent/BRPI0607323B1/pt
Publication of BRPI0607323B8 publication Critical patent/BRPI0607323B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1275—Streptococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1285—Gram-positive bacteria from Corynebacterium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1289—Mycobacteriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56938—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)

Abstract

COMPOSIçõES E USO DE POLIPEPTìDEOS E KITS PARA A DETECçãO DE ANTICORPO QUE SE LIGA ESPECIFICAMENTE A UM POLIPEPTìDEO. A presente invenção fornece polipeptideos isolados que podem ser isolados partindo de um Staphylococcus spp. São também fornecidas pela presente invenção composições que incluem um ou mais dos polipeptideos e métodos para a produção e métodos para a utilização dos polipeptideos.
BRPI0607323A 2005-02-14 2006-02-14 composições, usos de polipeptídeos e de anticorpos, bem como kits para a detecção de anticorpo que se liga especificamente a um polipeptídeo BRPI0607323B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US65284305P 2005-02-14 2005-02-14
US60/652,843 2005-02-14
PCT/US2006/005058 WO2006088803A2 (en) 2005-02-14 2006-02-14 Polypeptides from staphylococcus aureus and methods of use

Publications (3)

Publication Number Publication Date
BRPI0607323A2 true BRPI0607323A2 (pt) 2009-09-01
BRPI0607323B1 BRPI0607323B1 (pt) 2020-12-22
BRPI0607323B8 BRPI0607323B8 (pt) 2021-05-25

Family

ID=36694403

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0607323A BRPI0607323B8 (pt) 2005-02-14 2006-02-14 composições, usos de polipeptídeos e de anticorpos, bem como kits para a detecção de anticorpo que se liga especificamente a um polipeptídeo

Country Status (12)

Country Link
US (13) US8007811B2 (pt)
EP (1) EP1853306B1 (pt)
JP (3) JP2008532935A (pt)
CN (2) CN101119744B (pt)
AU (1) AU2006214534B2 (pt)
BR (1) BRPI0607323B8 (pt)
CA (1) CA2597263C (pt)
DK (1) DK1853306T3 (pt)
ES (1) ES2586125T3 (pt)
MX (1) MX2007009828A (pt)
NZ (4) NZ560612A (pt)
WO (1) WO2006088803A2 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830479A (en) * 1994-02-09 1998-11-03 Willmar Poultry Company, Inc. Active immunization using a siderophore receptor protein
WO1995021627A1 (en) * 1994-02-09 1995-08-17 Willmar Poultry Company, Inc. Active immunization using a siderophore receptor protein
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
CA2433561C (en) * 2001-01-03 2014-04-01 Willmar Poultry Company, Inc. Compositions including gram negative siderophore receptor proteins and methods of use
EP1678316B1 (en) 2003-09-19 2011-08-17 Epitopix, LLC Campylobacter polypeptides and methods of use
NZ560612A (en) * 2005-02-14 2011-01-28 Epitopix Llc Polypeptides from staphylococcus aureus and methods of use
AU2007221321B2 (en) * 2006-02-22 2012-06-28 The Texas A & M University System Antibodies recognizing a highly expressed putative antigen of CA-MRSA and methods of use
JP5564249B2 (ja) * 2006-06-23 2014-07-30 アレシア・バイオセラピューティクス・インコーポレーテッド 癌に関与するポリヌクレオチド配列およびポリペプチド配列
WO2010060186A1 (en) 2008-11-03 2010-06-03 Alethia Biotherapeutics Inc. Antibodies that specifically block the biological activity of a tumor antigen
EP2411046B1 (en) * 2009-03-23 2017-12-06 Epitopix, LLC Polypeptides and immunizing compositions containing gram positive polypeptides and methods of use
JP6294221B2 (ja) 2011-03-31 2018-03-14 アー・デー・ツェー・セラピューティクス・エス・アー 腎臓関連抗原１に対する抗体およびその抗原結合性フラグメント
TR201908872T4 (tr) 2012-01-09 2019-07-22 Adc Therapeutics Sa Üçlü negatif meme kanserini tedavi etmek için ajanlar.
US9169477B2 (en) 2012-01-27 2015-10-27 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Compositions and methods for immunization against bacteria expressing a carbapenemase
US10100093B2 (en) 2013-12-31 2018-10-16 Epitopix Llc Polypeptides and immunizing compositions containing Burkholderia polypeptides and methods of use
US11000582B2 (en) 2015-07-10 2021-05-11 Epitopix, Llc Proteins and immunizing compositions containing klebsiella proteins and methods of use
WO2017024038A1 (en) * 2015-08-03 2017-02-09 The Arizona Board Of Regents On Behalf Of The University Of Arizona Solar concentrator for a tower-mounted central receiver
US10166280B2 (en) 2016-06-08 2019-01-01 Epitopix, Llc Polypeptides and immunizing compositions containing Bacillus polypeptides and methods of use
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
TWI733412B (zh) * 2020-04-13 2021-07-11 華邦電子股份有限公司 具有氣隙之半導體元件及其製造方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4981685A (en) 1986-03-07 1991-01-01 Utah State University Foundation Bacterial extract vaccines for veterinary application
US5554372A (en) 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
US5292869A (en) 1989-04-27 1994-03-08 The Board Of Governors Of The University Method for isolating and purifying transferrin and lactoferrin receptor proteins from bacteria and the preparation of vaccines containing the same
WO1995021627A1 (en) 1994-02-09 1995-08-17 Willmar Poultry Company, Inc. Active immunization using a siderophore receptor protein
US5830479A (en) 1994-02-09 1998-11-03 Willmar Poultry Company, Inc. Active immunization using a siderophore receptor protein
US5538733A (en) 1994-07-07 1996-07-23 Willmar Poultry Company, Inc. Method of priming an immune response in a one-day old animal
US6403337B1 (en) * 1996-01-05 2002-06-11 Human Genome Sciences, Inc. Staphylococcus aureus genes and polypeptides
EP0950068B1 (en) * 1996-05-16 2005-11-09 THE TEXAS A&M UNIVERSITY SYSTEM Collagen binding protein compositions and methods of use
US6680195B1 (en) 1997-11-26 2004-01-20 Inhibitex, Inc. Extracellular matrix-binding proteins from staphylococcus aureus
US6692739B1 (en) 1998-08-31 2004-02-17 Inhibitex, Inc. Staphylococcal immunotherapeutics via donor selection and donor stimulation
US6703025B1 (en) 1998-08-31 2004-03-09 Inhibitex, Inc. Multicomponent vaccines
US6682754B2 (en) 1999-11-24 2004-01-27 Willmar Poultry Company, Inc. Ovo delivery of an immunogen containing implant
WO2001070955A2 (en) 2000-03-21 2001-09-27 Elitra Pharmaceuticals, Inc. Identification of essential genes in prokaryotes
AT410173B (de) 2000-06-08 2003-02-25 Cistem Biotechnologies Gmbh Antigene zusammensetzung
CA2433561C (en) * 2001-01-03 2014-04-01 Willmar Poultry Company, Inc. Compositions including gram negative siderophore receptor proteins and methods of use
AT410798B (de) 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
CA2450939C (en) 2001-06-15 2012-11-06 The Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Cross-reactive monoclonal and polyclonal antibodies which recognize surface proteins from coagulase-negative staphylococci and staphylococcus aureus
WO2003020875A2 (en) * 2001-06-17 2003-03-13 D-Squared Biotechnologies, Inc. Staphylococci surface-exposed immunogenic polypeptides
US6720160B2 (en) 2001-10-11 2004-04-13 Helica Biosystems, Inc. Method for simultaneous detection of multiple microbial antigens in biological specimens from mastitic animals
AU2003254555A1 (en) 2002-07-26 2004-02-23 Intercell Ag S. aureus antigene
US6947260B2 (en) * 2002-11-18 2005-09-20 Hitachi Global Storage Technologies Netherlands B.V. System and method of damping vibration on coil supports in high performance disk drives with rotary actuators
EP1678316B1 (en) 2003-09-19 2011-08-17 Epitopix, LLC Campylobacter polypeptides and methods of use
US20070128183A1 (en) 2004-04-27 2007-06-07 Intercell Ag Td antigens
EP1784220B1 (en) 2004-08-26 2017-12-20 The University Of Western Ontario Bacterial iron acquisition targets
CA2581746A1 (en) 2004-10-25 2006-06-08 The University Of Western Ontario Staphylococcus aureus isd protein-based anti-infectives
NZ560612A (en) 2005-02-14 2011-01-28 Epitopix Llc Polypeptides from staphylococcus aureus and methods of use
EP2411046B1 (en) 2009-03-23 2017-12-06 Epitopix, LLC Polypeptides and immunizing compositions containing gram positive polypeptides and methods of use

Also Published As

Publication number Publication date
WO2006088803A3 (en) 2006-12-21
US8007803B2 (en) 2011-08-30
US9266944B2 (en) 2016-02-23
US20060233824A1 (en) 2006-10-19
US8961979B2 (en) 2015-02-24
US20130280300A1 (en) 2013-10-24
CA2597263C (en) 2017-01-17
US20160158312A1 (en) 2016-06-09
CN103143006B (zh) 2016-08-03
US20130288952A1 (en) 2013-10-31
JP2013053155A (ja) 2013-03-21
US20170182146A1 (en) 2017-06-29
NZ597997A (en) 2013-10-25
AU2006214534A1 (en) 2006-08-24
HK1117746A1 (en) 2009-01-23
US9981028B2 (en) 2018-05-29
MX2007009828A (es) 2007-09-27
CN101119744A (zh) 2008-02-06
US20120164685A1 (en) 2012-06-28
US20130287813A1 (en) 2013-10-31
US9623076B2 (en) 2017-04-18
CN103143006A (zh) 2013-06-12
US20150210757A1 (en) 2015-07-30
AU2006214534B2 (en) 2012-07-19
NZ560612A (en) 2011-01-28
BRPI0607323B1 (pt) 2020-12-22
NZ589238A (en) 2012-02-24
US20140005360A1 (en) 2014-01-02
US8709760B2 (en) 2014-04-29
US20070087011A1 (en) 2007-04-19
NZ613923A (en) 2015-02-27
EP1853306B1 (en) 2016-06-15
US8709436B2 (en) 2014-04-29
EP1853306A2 (en) 2007-11-14
JP2015155457A (ja) 2015-08-27
WO2006088803A2 (en) 2006-08-24
US20100221253A1 (en) 2010-09-02
JP2008532935A (ja) 2008-08-21
ES2586125T3 (es) 2016-10-11
DK1853306T3 (en) 2016-09-05
US20150023969A1 (en) 2015-01-22
JP6100826B2 (ja) 2017-03-22
US8025885B2 (en) 2011-09-27
BRPI0607323B8 (pt) 2021-05-25
US8007811B2 (en) 2011-08-30
US20160068590A9 (en) 2016-03-10
CA2597263A1 (en) 2006-08-24
US20080200650A1 (en) 2008-08-21
CN101119744B (zh) 2013-03-13

Similar Documents

Publication Publication Date Title
BRPI0607323A2 (pt) composições e uso de polipeptìdeos e kits para a detecção de anticorpo que se liga especificamente a um polipeptìdeo
CY1124802T1 (el) Δεσμευτικοι παραγοντες σκληροστινης
CY1121291T1 (el) Ανοσοδοκιμασιες ενισχυσης σηματος
EA200970210A1 (ru) Prlr-специфическое антитело и его применения
CY1120951T1 (el) Ανθρωπινα αντισωματα enanti-tau
BR112013023540A2 (pt) anticorpo, kit e método para a determinação de peptídeos amilóides
MX2007010349A (es) Composiciones y metodos para clasificar muestras biologicas.
ECSP088543A (es) Anticuerpos anti-ox40l y métodos que los utilizan
ECSP099027A (es) Anticuerpos anti-dll4 y métodos que los usan
BRPI0812878B8 (pt) anticorpo isolado ou parte funcional do mesmo, vetor, método para produzir um anticorpo ou uma parte funcional do mesmo, para produzir uma célula produtora de anticorpo e para produzir um anticorpo capaz de se ligar especificamente a rsv, composição, e, uso de um anticorpo ou parte funcional do mesmo ou de uma composição ou de vetor
CO6351750A2 (es) Composiciones y métodos para anticuerpos que se dirigen a la proteina de complementos c5
BRPI0909044B8 (pt) anticorpo que se liga especificamente ao csf-1r humano,composição farmacêutica e uso dos mesmos
AR057237A1 (es) Metodos y composiciones para actuar sobre la poliubiquitina
DE602006015793D1 (de) Proteolipidmembran und lipidmembranen-biosensor
WO2009007846A3 (en) Methods for modifying, isolating, detecting, visualizing, and quantifying citrullinated and/or homocitrullinated peptides, polypeptides and proteins
BRPI0606506A2 (pt) polipeptìdeos de yersinia spp. e métodos de uso
DK2021794T3 (da) Anvendelse af protein S100A 12 som en markør for colorektal cancer
BR112012019475A2 (pt) "uso de um anticorpo monoclonal anti-cd 44 anticorpo anti-cd44 humanizado e kit para a detecção da presença de hnscc em uma amostra
AR059096A1 (es) Anticuerpos anti- efrina -b2 y metodos que usan estos
DK1987357T3 (da) Polypeptider, som genkendes af anti-Trichinella-antistoffer, og anvendelser deraf
ATE476655T1 (de) Doxorubicin-immuntest
EA200702361A1 (ru) АНТИТЕЛА ПРОТИВ csPCNA ИЗОФОРМЫ И ИХ ПРИМЕНЕНИЕ
DE602006007967D1 (de) Gegen das gemeinsame epitop von mutierten p53 gerichtete humane synthetische einzelkettenantikörper und anwendungen davon
BRPI0514672A (pt) polipeptìdeos de fusobacterium e métodos de uso
ATE489623T1 (de) Peptide zum nachweis von ehrlichia ewingii antikörper

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 22/12/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/02/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 20A ANUIDADE.